RxDoctor Payments Data

George Profeta, MD

Pulmonary Disease · New Windsor, NYNPI 1831282912

Payments from drug & device makers

$3,287in general payments, 2019–2025

Across 176 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$703
  • Pfizer$396
  • Boehringer Ingelheim$231
  • Verona Pharma, Inc.$153
  • Electromed, Inc.$115
  • plus $294 from 7 others

What the payments were for

  • Food & beverage$3,287100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,287 in reported general payments places this provider in the 65th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$525,348
Medicare patients
1,321
Services billed
8,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter205$256,066
Breztri AerosphereBudesonide/Glycopyr/Formoterol65$86,930
FarxigaDapagliflozin Propanediol36$48,335
RybelsusSemaglutide17$45,331
EliquisApixaban25$29,238
Breo ElliptaFluticasone/Vilanterol35$25,629
XareltoRivaroxaban18$24,231
JardianceEmpagliflozin14$20,996
Incruse ElliptaUmeclidinium Bromide28$20,434
Combivent RespimatIpratropium/Albuterol Sulfate30$19,108
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$13,554
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$11,755
Pirfenidone15$10,681
Albuterol Sulfate HfaAlbuterol Sulfate252$10,181
SymbicortBudesonide/Formoterol Fumarate15$7,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$1,395$313,884284 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$703$142,496116 claims
Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat$231$53,65762 claims
Novo NordiskRybelsus$66$45,33117 claims
PfizerEliquis$396$29,23825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in New Windsor

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →